CA3020378C - Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer - Google Patents

Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer

Info

Publication number
CA3020378C
CA3020378C CA3020378A CA3020378A CA3020378C CA 3020378 C CA3020378 C CA 3020378C CA 3020378 A CA3020378 A CA 3020378A CA 3020378 A CA3020378 A CA 3020378A CA 3020378 C CA3020378 C CA 3020378C
Authority
CA
Canada
Prior art keywords
chloro
tridecaene
dithia
methyl
pentaazaheptacyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3020378A
Other languages
English (en)
Other versions
CA3020378A1 (fr
Inventor
Alexander Hird
Matthew Alan Belmonte
Wenzhan YANG
John Paul SECRIST
Daniel William Robbins
Steven Lee Kazmirski
Dedong Wu
Bo Peng
Jeffrey JOHANNES
Michelle Laurae LAMB
Qing Ye
XiaoLan Zheng
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority claimed from PCT/EP2017/059511 external-priority patent/WO2017182625A1/fr
Publication of CA3020378A1 publication Critical patent/CA3020378A1/fr
Application granted granted Critical
Publication of CA3020378C publication Critical patent/CA3020378C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne un composé qui est l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique (formule 1), des énantiomères et des sels pharmaceutiquement acceptables correspondants. L'invention concerne également des compositions pharmaceutiques de l'acide 17-chloro-5,13,14,22-tétraméthyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridécaène-23-carboxylique, et des énantiomères et des sels pharmaceutiquement acceptables correspondants, et des méthodes de traitement du cancer avec ces composés et ces compositions.
CA3020378A 2016-04-22 2017-04-21 Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer Active CA3020378C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
US62/326,156 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (fr) 2016-04-22 2017-04-21 Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer

Publications (2)

Publication Number Publication Date
CA3020378A1 CA3020378A1 (fr) 2017-10-26
CA3020378C true CA3020378C (fr) 2024-07-02

Family

ID=

Similar Documents

Publication Publication Date Title
US11472816B2 (en) Mcl-1 inhibitors and methods of use thereof
US11352369B2 (en) Pyridine and pyrimidine derivatives
AU2017251537B2 (en) Bromodomain inhibitors
EP2797918B1 (fr) Inhibiteurs de bromodomaine
WO2018178226A1 (fr) Inhibiteurs de mcl-1 et procédés d'utilisation associés
EP3288931B1 (fr) Inhibiteurs de certaines protéines kinases
WO2017114351A1 (fr) Inhibiteurs de certaines protéines kinases
AU2014244194A1 (en) Pyrrolopyrimindine CDK9 kinase inhibitors
WO2017133663A1 (fr) Composés contenant du phosphore en tant qu'inhibiteurs de la protéine kinase
CA3020378C (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
HK1262770A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1262770B (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1260481B (zh) 用於治疗癌症的大环mcl-1抑制剂
HK1260481A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
HK1203508B (en) Bromodomain inhibitors